{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:58:26Z","timestamp":1792814306884,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01017"],"award-info":[{"award-number":["PI22\/01017"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-22-198"],"award-info":[{"award-number":["BCRF-22-198"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-23-198"],"award-info":[{"award-number":["BCRF-23-198"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69222-5","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:45:20Z","timestamp":1771238720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-3183","authenticated-orcid":false,"given":"Tom\u00e1s","family":"Pascual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-5727","authenticated-orcid":false,"given":"Maria","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Cejalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6586-1712","authenticated-orcid":false,"given":"Sergi","family":"Ganau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda Julve","family":"Parre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4813-5946","authenticated-orcid":false,"given":"Ignacio","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5440-9643","authenticated-orcid":false,"given":"Fara","family":"Bras\u00f3-Maristanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"de la Cruz-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-1648","authenticated-orcid":false,"given":"Manel","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Gonz\u00e0lez-Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samyukta","family":"Chillara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Villagrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4924-1767","authenticated-orcid":false,"given":"Adam D.","family":"Pfefferle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2881-5829","authenticated-orcid":false,"given":"Constandina E.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8796-8812","authenticated-orcid":false,"given":"Juan M.","family":"Ferrero-Cafiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-8799","authenticated-orcid":false,"given":"Mafalda","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Perou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"69222_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat, A. et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 21, 33\u201343 (2020).","journal-title":"Lancet Oncol."},{"key":"69222_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0540-z","volume":"13","author":"A Prat","year":"2015","unstructured":"Prat, A. et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 13, 303 (2015).","journal-title":"BMC Med."},{"key":"69222_CR3","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl, S. et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer\u2014the penelope-B trial. J. Clin. Oncol. 39, 1518\u20131530 (2021).","journal-title":"J. Clin. Oncol."},{"key":"69222_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164\u2013172 (2014).","journal-title":"Lancet"},{"key":"69222_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-20-3105","volume":"27","author":"H Soliman","year":"2021","unstructured":"Soliman, H. et al. A phase I trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer. Clin. Cancer Res. 27, 1012\u20131018 (2021).","journal-title":"Clin. Cancer Res."},{"key":"69222_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292\u2013303 (2003).","journal-title":"Gene Ther."},{"key":"69222_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2217\/imt-2019-0033","volume":"11","author":"SS Raman","year":"2019","unstructured":"Raman, S. S., Hecht, J. R. & Chan, E. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy 11, 705\u2013723 (2019).","journal-title":"Immunotherapy"},{"key":"69222_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens, L. A. et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 5, 74\u201382 (2019).","journal-title":"JAMA Oncol."},{"key":"69222_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer \u2014 expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91\u2013113 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"69222_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/sj.cgt.7700946","volume":"13","author":"Y Shen","year":"2006","unstructured":"Shen, Y. & Nemunaitis, J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 13, 975\u2013992 (2006).","journal-title":"Cancer Gene Ther."},{"key":"69222_CR11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119.e1110 (2017).","journal-title":"Cell"},{"key":"69222_CR12","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36, 1658\u20131667 (2018).","journal-title":"J. Clin. Oncol."},{"key":"69222_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","volume":"6","author":"CM Kelly","year":"2020","unstructured":"Kelly, C. M. et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol. 6, 402\u2013408 (2020).","journal-title":"JAMA Oncol."},{"key":"69222_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-023-02309-4","volume":"29","author":"H Soliman","year":"2023","unstructured":"Soliman, H. et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat. Med. 29, 450\u2013457 (2023).","journal-title":"Nat. Med."},{"key":"69222_CR15","doi-asserted-by":"crossref","unstructured":"Long, G. et al. Long\u2011term analysis of MASTERKEY\u2011265 phase 1b trial of talimogene laherparepvec (T\u2011VEC) plus pembrolizumab in patients with unresectable stage IIIB\u2013IVM1c melanoma. J. Immunother. Cancer 8, 429 (2020).","DOI":"10.1136\/jitc-2020-SITC2020.0429"},{"key":"69222_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney, J. A. et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J. Clin. Oncol. 41, 528\u2013540 (2023).","journal-title":"J. Clin. Oncol."},{"key":"69222_CR17","doi-asserted-by":"crossref","unstructured":"Villacampa, G. et al. Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis. JAMA Oncol. 10, 1331\u20131341 (2024).","DOI":"10.1001\/jamaoncol.2024.3456"},{"key":"69222_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/annonc\/mdu235","volume":"25","author":"C Denkert","year":"2014","unstructured":"Denkert, C. The immunogenicity of breast cancer\u2014molecular subtypes matter. Ann. Oncol. 25, 1453\u20131455 (2014).","journal-title":"Ann. Oncol."},{"key":"69222_CR19","doi-asserted-by":"publisher","unstructured":"Falato, C., Schettini, F., Pascual, T., Bras\u00f3-Maristany, F. & Prat, A. Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. Cancer Treatment Rev. 112 https:\/\/doi.org\/10.1016\/j.ctrv.2022.102496 (2023).","DOI":"10.1016\/j.ctrv.2022.102496"},{"key":"69222_CR20","doi-asserted-by":"crossref","unstructured":"Clark, A. S. et al. A phase II randomized study of paclitaxel alone or combined with pelareorep with or without avelumab in metastatic hormone receptor\u2013positive breast cancer: The BRACELET-01\/PrE0113 study. Clin. Cancer Res. 31, 2655\u20132662 (2025).","DOI":"10.1158\/1078-0432.CCR-24-2701"},{"key":"69222_CR21","doi-asserted-by":"publisher","unstructured":"Prat, A. et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. eBioMedicine 75 https:\/\/doi.org\/10.1016\/j.ebiom.2021.103801 (2022).","DOI":"10.1016\/j.ebiom.2021.103801"},{"key":"69222_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-4-3","volume":"4","author":"C Fan","year":"2011","unstructured":"Fan, C. et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med. Genomics 4, 3 (2011).","journal-title":"BMC Med. Genomics"},{"key":"69222_CR23","doi-asserted-by":"publisher","unstructured":"Conte, B. et al. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies. eBioMedicine 102 https:\/\/doi.org\/10.1016\/j.ebiom.2024.105043 (2024).","DOI":"10.1016\/j.ebiom.2024.105043"},{"key":"69222_CR24","doi-asserted-by":"publisher","unstructured":"Villacampa, G. et al. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network\u2014Breast dataset (SCAN-B). ESMO Open 9 https:\/\/doi.org\/10.1016\/j.esmoop.2024.102388 (2024).","DOI":"10.1016\/j.esmoop.2024.102388"},{"key":"69222_CR25","doi-asserted-by":"publisher","unstructured":"Mar\u00edn-Aguilera, M. et al. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer. ESMO Open 9 https:\/\/doi.org\/10.1016\/j.esmoop.2024.102903 (2024).","DOI":"10.1016\/j.esmoop.2024.102903"},{"key":"69222_CR26","doi-asserted-by":"publisher","unstructured":"Lee, S. et al. B-cell\u2013mediated immunity predicts survival of patients with estrogen receptor\u2013positive breast cancer. JCO Precision Oncol. e2300263 https:\/\/doi.org\/10.1200\/po.23.00263 (2024).","DOI":"10.1200\/po.23.00263"},{"key":"69222_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1513750","volume":"375","author":"JW Park","year":"2016","unstructured":"Park, J. W. et al. Adaptive randomization of neratinib in early breast cancer. N. Engl. J. Med. 375, 11\u201322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"69222_CR28","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N. Engl. J. Med. 391, 1981\u20131991 (2024).","journal-title":"N. Engl. J. Med."},{"key":"69222_CR29","doi-asserted-by":"crossref","unstructured":"Mittendorf, E. A. et al. Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial. Nat. Med. 31, 1\u20138 (2025).","DOI":"10.1038\/s41591-025-03725-4"},{"key":"69222_CR30","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni, L. et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann. Oncol. 33, 534\u2013543 (2022).","journal-title":"Ann. Oncol."},{"key":"69222_CR31","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans, W. F. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25, 4414\u20134422 (2007).","journal-title":"J. Clin. Oncol."},{"key":"69222_CR32","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"69222_CR33","unstructured":"Dieci, M. V. et al. Seminars in Cancer Biology 16\u201325 (Elsevier, 2018)."},{"key":"69222_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"69222_CR35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"69222_CR36","doi-asserted-by":"publisher","first-page":"S1149","DOI":"10.1016\/j.annonc.2023.09.1260","volume":"34","author":"N Harbeck","year":"2023","unstructured":"Harbeck, N. et al. 2232O Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): exploratory biomarker analysis from IMpassion031. Ann. Oncol. 34, S1149\u2013S1150 (2023).","journal-title":"Ann. Oncol."},{"key":"69222_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nbt1385","volume":"26","author":"GK Geiss","year":"2008","unstructured":"Geiss, G. K. et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26, 317\u2013325 (2008).","journal-title":"Nat. Biotechnol."},{"key":"69222_CR38","doi-asserted-by":"crossref","unstructured":"Prat, A. et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. eBioMedicine 75, 103801 (2022).","DOI":"10.1016\/j.ebiom.2021.103801"},{"key":"69222_CR39","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160 (2009).","journal-title":"J. Clin. Oncol."},{"key":"69222_CR40","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","volume":"16","author":"TO Nielsen","year":"2010","unstructured":"Nielsen, T. O. et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor\u2013positive breast cancer. Clin. Cancer Res. 16, 5222\u20135232 (2010).","journal-title":"Clin. Cancer Res."},{"key":"69222_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"69222_CR42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"69222_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaoncol.2022.6288","volume":"9","author":"A Fernandez-Martinez","year":"2023","unstructured":"Fernandez-Martinez, A. et al. Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2\/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials. JAMA Oncol. 9, 490\u2013499 (2023).","journal-title":"JAMA Oncol."},{"key":"69222_CR44","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1073\/pnas.091062498","volume":"98","author":"VG Tusher","year":"2001","unstructured":"Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98, 5116\u20135121 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69222_CR45","doi-asserted-by":"publisher","unstructured":"Pascual, T. et al. PROMETEO analysis code for \u201cTalimogene Laherparepvec And Atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)\u201d. GitHub repository, archived at Zenodo. https:\/\/doi.org\/10.5281\/zenodo.17592894 (2025).","DOI":"10.5281\/zenodo.17592894"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69222-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69222-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69222-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:22:14Z","timestamp":1774534934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69222-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69222"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69222-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Potential conflicts of interest are the following: T.P. reports fees for non-CME services received directly from commercial interests or their agents (e.g., speakers\u2019 bureaus) from AstraZeneca, Novartis, Daiichi Sankyo, Pfizer, Veracyte, Argenetics, Gilead, and Lilly; consulting fees (e.g., advisory boards) from Daiichi Sankyo, Novartis, and Gilead; and travel and accommodation support from Gilead, Daiichi Sankyo, and Roche. T.P. also declares a non-financial interest as a member of the Board of Directors of the SOLTI Cancer Research Group, a non-profit organization dedicated to breast cancer research. M.V. reports personal fees from Novartis, Daiichi Sankyo, AstraZeneca, Eli Lilly and Company, and Gilead outside the submitted work. J.M.C. reports travel expenses and speaker fees from AstraZeneca, Lilly, Pfizer, Gilead, Novartis and MSD. Es.S. declares advisory board membership for Astra Zeneca and consulting fees from Reveal Genomics INC. G.V. has received a speaker\u2019s fee from Pfizer, MSD, GSK and Pierre Fabrer, has held an advisory role with AstraZeneca and received consultant fees from Reveal Genomics. F.B.-M. reports part-time employment from Reveal Genomics and has patents filed: PCT\/EP2022\/086493, PCT\/EP2023\/060810, EP23382703 and EP23383369. El.S. declares personal fees for educational events and\/or material from Novartis, Pfizer, Eisai, and Daiichi Sankyo; advisory fees from Pfizer and Seagen; and travel\/accommodation expenses from Gilead, Daiichi Sankyo, Novartis, and Lilly. L.C.-M. reports advisory and consulting fees from BMS, MSD, Novartis, Daiichi Sankyo, Gilead, lecture fees from Gilead, MSD, institutional financial interests from Roche and BMS. X.G.-F: reports speaker honoraria from Gilead, Novartis, and Pierre Fabre, travel\/congress expenses from Eli Lilly, and speaker honoraria and travel\/congress expenses from Astra Zeneca; P.V. is a stockholder of Reveal Genomics; reports personal fees from NanoString Technologies. M.O. reports institutional grant\/research from AstraZeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Genentech, Gilead, GSK, Immutep, Roche, Seagen, Zenith Epigenetics, advisory and consulting fees or speaker honoraria from AstraZeneca, Cureos Science, Daiichi-Sankyo \/ AstraZeneca, Gilead, iTEOS, Lilly, MSD, Relay Therapeutics, Roche, Seagen, Eisai, Libbs, Novartis, Pfizer, travel grants from AstraZeneca, Eisai, Gilead, Pierre-Fabre, and non-financial disclosure as the SOLTI Breast Cancer Group president elected. C.M.P. is an equity stockholder and consultant of BioClassifier LLC and Reveal Genomics; also listed as an inventor on patent applications for the Breast PAM50 Subtyping assay. A.P. reports advisory and consulting fees from AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo, and Peptomyc, lecture fees from AstraZeneca, Roche, Novartis, and Daiichi Sankyo, institutional financial interests from AstraZeneca, Novartis, Roche, and Daiichi Sankyo; stockholder and employee of Reveal Genomics; patents filed PCT\/EP2016\/080056, PCT\/EP2022\/086493, PCT\/EP2023\/060810, EP23382703 and EP23383369. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2817"}}